Therapeutic strategy targeting Jak3 for systemic lupus erythematosus

investigate the effectiveness of Jak inhibition on systemic lupus erythematosuscp 690550,a Jak3 specific inhibitor was utilized. CP690、550 strongly suppressed CD4+ T cell proliferation andproduction of IFN- and IL-17, induced by CD3 and CD28 stimuli，in a dose dependent manner. However, CP690,550 did not affect B cell proliferation，induced by BCR and sCD40L stimuli. Moreover，CP690、550 also suppressed mRNA表达式和IL-17 in a dose dependent manner，但是不induced CD4+ T cell apoptosis. Becasuse previous reports have pointed out the enhancedproduction of IFN- and IL-17 in SLE patient，our results indicate the可能性effectiveness of Jak3 inhibition on SLE。

To investigate the effectiveness of Jak inhibition on systemic lupus erythematosus (SLE), CP690,550, a Jak3 specific inhibitor was utilized. CP690,550 strongly suppressed CD4+ T cell proliferation and production of IFN-・ and IL-17, induced by CD3 and CD28 stimuli, in a dose dependent manner. However, CP690,550 did not affect B cell proliferation, induced by BCR and sCD40L stimuli. Moreover, CP690,550 also suppressed mRNA expression of IFN-・ and IL-17 in a dose dependent manner, but did not induced CD4+ T cell apoptosis. Becasuse previous reports have pointed out the enhanced production of IFN-・ and IL-17 in SLE patient, our results indicate the possible effectiveness of Jak3 inhibition on SLE.